CAR-T Cell Therapy - Chimeric Antigen Receptor T-cell Immunotherapy

Advanced immunotherapy for multiple myeloma, lymphoma, and leukemia. ORR up to 96.4% with total cost $200,000-$250,000, far lower than Western countries. Enrollment in 2-4 weeks.

Chimeric Antigen Receptor T-cell immunotherapy treating blood cancers with world-class clinical outcomes.

  • Multiple Myeloma
  • High-grade Lymphoma
  • Acute Lymphoblastic Leukemia (ALL)
  • Other B-cell malignancies
  • ORR up to 96.4% for multiple myeloma
  • Cost advantage: $200K-$250K vs $500K+ in West
  • Minimal waiting: 2-4 weeks vs 6-12 months
  • Over 4,000 infusions completed
  • Flexible clinical trial access

Evaluation → Cell collection → CAR-T preparation → Infusion → Monitoring → Follow-up

CAR-T细胞疗法 - 嵌合抗原受体T细胞免疫治疗

用于治疗多发性骨髓瘤、淋巴瘤和白血病的先进免疫疗法。总缓解率高达96.4%，总费用20-25万美元，远低于欧美国家。2-4周即可入组。

嵌合抗原受体T细胞免疫疗法，以世界级临床成果治疗血液癌症。

  • 多发性骨髓瘤
  • 高级别淋巴瘤
  • 急性淋巴细胞白血病(ALL)
  • 其他B细胞恶性肿瘤
  • 多发性骨髓瘤ORR高达96.4%
  • 费用优势：20-25万vs欧美50万+
  • 等待时间极短：2-4周vs6-12个月
  • 已完成超4000例输注
  • 灵活的临床试验通道

评估 → 细胞采集 → CAR-T制备 → 输注 → 监测 → 随访